1. Home
  2. AKBA vs JMSB Comparison

AKBA vs JMSB Comparison

Compare AKBA & JMSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

N/A

Current Price

$0.95

Market Cap

343.4M

Sector

Health Care

ML Signal

N/A

Logo John Marshall Bancorp Inc.

JMSB

John Marshall Bancorp Inc.

N/A

Current Price

$23.19

Market Cap

308.2M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
AKBA
JMSB
Founded
2007
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
343.4M
308.2M
IPO Year
2014
2022

Fundamental Metrics

Financial Performance
Metric
AKBA
JMSB
Price
$0.95
$23.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$4.67
$23.00
AVG Volume (30 Days)
8.2M
51.1K
Earning Date
05-07-2026
04-29-2026
Dividend Yield
N/A
1.72%
EPS Growth
93.94
24.17
EPS
N/A
0.93
Revenue
N/A
N/A
Revenue This Year
N/A
$17.09
Revenue Next Year
N/A
$10.03
P/E Ratio
N/A
$24.69
Revenue Growth
N/A
N/A
52 Week Low
$0.81
$18.50
52 Week High
$3.19
$24.26

Technical Indicators

Market Signals
Indicator
AKBA
JMSB
Relative Strength Index (RSI) 46.52 51.48
Support Level $0.84 $22.54
Resistance Level $0.96 $24.08
Average True Range (ATR) 0.06 0.71
MACD 0.02 -0.00
Stochastic Oscillator 52.22 40.56

Price Performance

Historical Comparison
AKBA
JMSB

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

About JMSB John Marshall Bancorp Inc.

John Marshall Bancorp Inc is a bank holding company. Through its banking subsidiary, it offers banking products and financial services to small to medium-sized businesses, professional corporations, non-profits, and individuals. The products and services offered by the company include commercial checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential and commercial construction and development loans, online banking, and mobile banking. The firm serves local businesses, professionals, individuals, and families throughout the Washington, D.C. metropolitan area.

Share on Social Networks: